175 related articles for article (PubMed ID: 21034860)
1. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine.
Zaman M; Skwarczynski M; Malcolm JM; Urbani CN; Jia Z; Batzloff MR; Good MF; Monteiro MJ; Toth I
Nanomedicine; 2011 Apr; 7(2):168-73. PubMed ID: 21034860
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
[TBL] [Abstract][Full Text] [Related]
4. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
5. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
[TBL] [Abstract][Full Text] [Related]
6. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
7. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
9. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I
Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
12. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
[TBL] [Abstract][Full Text] [Related]
13. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.
Vohra H; Dey N; Gupta S; Sharma AK; Kumar R; McMillan D; Good MF
Res Microbiol; 2005 May; 156(4):575-82. PubMed ID: 15862457
[TBL] [Abstract][Full Text] [Related]
14. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
15. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
[TBL] [Abstract][Full Text] [Related]
16. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
[TBL] [Abstract][Full Text] [Related]
17. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.
Zaman M; Abdel-Aal AB; Fujita Y; Phillipps KS; Batzloff MR; Good MF; Toth I
PLoS One; 2012; 7(1):e30146. PubMed ID: 22253911
[TBL] [Abstract][Full Text] [Related]
18. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
19. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
20. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
